Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors  by Ho, Chen-Hsun et al.
872 J Formos Med Assoc | 2009 • Vol 108 • No 11
ORIGINAL ARTICLE
Bladder cancer is the second most common 
genitourinary malignancy, and > 90% of all pri-
mary bladder cancer is transitional cell carcinoma
(TCC). In 2005 alone, 1900 new patients were
diagnosed with bladder cancer in Taiwan, and
747 patients died of the disease.1 At presenta-
tion, about 70% of patients present with superficial
bladder cancer (Ta, T1, or CIS); the remainder
present with or develop invasive disease (muscle-
invasive, locally advanced, or metastatic disease).
Radical cystectomy remains the gold standard for
the treatment for muscle-invasive bladder cancer,
although bladder-sparing treatment is appropri-
ate in selected patients.
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Background/Purpose: To better understand the result of radical cystectomy in the treatment of bladder
cancer, we analyzed our data and reported the oncological outcomes and survival predictors.
Methods: Patients underwent radical cystectomy for bladder transitional cell carcinoma between March
1995 and July 2007 were evaluated. The clinical course, pathological characteristics, and clinical outcomes
were described and analyzed.
Results: A total of 148 patients (98 men and 50 women) with a median age of 66.7 years (range: 23.8–83.3)
were included in the study. Median follow-up was 64 months. The perioperative mortality was 2.7%. The 
5-year recurrence-free survival (RFS) and overall survival (OS) for all 148 patients was 61% and 53%, respec-
tively. The 5-year RFS and OS were 68% and 62% for pT2, 65% and 59% for pT3, 11% and 9% for pT4, and
37% and 31% for nodal-positive disease, respectively. The number of positive lymph nodes was significantly
associated with survival: 5-year RFS and OS were 54% and 33%, for patients with only 1–3 positive lymph
nodes, whereas, all patients with ≥ 4 positive lymph nodes had recurrence. On multivariate analysis, age
> 60 years, pT4 tumors, and lymph node involvement had a negative impact on survival.
Conclusion: Radical cystectomy can be curative in a significant portion of patients with organ-confined
(T2 or less) and extravesical (pT3) bladder cancer. Age > 60 years, pT4 tumors, and nodal metastases were
associated with poor prognosis. Patients with limited lymph node involvement (1–3 nodes) can 
be cured by surgery alone, whereas a more extensive lymph node metastasis (≥ 4 nodes) eventually results
in recurrence. Concomitant prostate cancer is of low grade and early stage, and is clinically insignificant. 
[J Formos Med Assoc 2009;108(11):872–878]
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We reviewed and analyzed retrospectively a se-
ries of patients who underwent radical cystectomy
for bladder cancer over the past 10 years. The 
oncological outcome and survival predictors are
reported in this paper.
Patients and Methods
Between March 1995 and July 2007, a total of
162 patients with bladder cancer underwent rad-
ical cystectomy at our institute (National Taiwan
University Hospital Taipai, Taiwan). Radical cys-
tectomy referred to radical cystoprostatectomy in
male patients and anterior exenteration in female
patients. For all patients, standard pelvic lymph
node dissection was performed. The borders of
lymph node dissection were composed of the
genitofemoral nerve laterally, the bladder wall
medially, the endopelvic fascia caudad, the bifur-
cation of the common iliac artery cephalad, and
the obturator fossa as the floor. All lymph nodes
along with the soft tissue in the space were re-
moved. Urinary diversion was performed with
one of the following methods: ileal conduit,
ileoneobladder, Indiana pouch, or percutaneous
nephrostomy. The choice of urinary diversion was
up to the surgeons, with consideration of the 
patients’ condition and preference.
The pathological diagnosis of the 162 patients
comprised 148 TCCs, four adenocarcinomas, two
squamous cell carcinomas, and one small cell
carcinoma. Data were incomplete in seven pa-
tients, who were excluded from the study. Only
patients with TCC were reviewed and analyzed
subsequently. The 1997 tumor–node–metasta-
sis (TNM) classification of the American Joint
Committee on Cancer was used for pathological
staging,2 and tumors were designated as pT0, pTis,
pTa, pT1, pT2, pT3, pT4, or pN+. Superficial dis-
eases (pTis, pTa, or pT1) were grouped together
for further analysis.
Postoperatively, patients were followed periodi-
cally, usually at 3-month intervals in the first 2
years, 6-month intervals in the following 3 years,
and annually thereafter. Physical examinations,
serum biochemistry tests, and urinalysis were per-
formed at every follow-up. Radiographic evaluation,
including abdominal/pelvic computed tomogra-
phy and chest radiography, was performed at 3- or
6-month intervals, and at least once a year. Bone
scans were performed electively when clinically 
indicated. Recurrence was indicated by any radio-
graphically and/or pathologically proven recurrent
tumors: they were defined as local recurrence 
if the mass was located in the pelvic cavity and as
distant recurrence if the mass appeared elsewhere.
Time to recurrence was calculated as the time
from cystectomy to the date of the first docu-
mented clinical recurrence; recurrence-free survival
(RFS) was calculated as the time from cystectomy
to the last follow-up if the patient had no evi-
dence of recurrence; patients who died before 
recurrence were censored at the time of death.
Overall survival (OS) was calculated as the time
from cystectomy to the date of death. All deaths,
regardless of cause, were counted as events; pa-
tients who were still alive were censored at the
date of last contact. Perioperative mortality was
defined as any death within 30 days of surgery or
before discharge.
Kaplan–Meier plots were used to estimate the
RFS and OS for the 148 TCCs classified by patho-
logical stage. The log-rank test was used to com-
pare subgroups of patients in terms of survival.
Cox regression was used to test survival predic-
tors in multivariate analysis. All p values reported
were two-sided, and p < 0.05 was considered to
indicate statistical significance. All data in the pres-
ent study were analyzed with the SPSS version 13.0
(SPSS Inc., Chicago, IL, USA).
Results
The demographic characteristics of the 148 pa-
tients with bladder TCC are shown in Table 1.
Ninety-eight (66.2%) were men and 50 (33.8%)
were women. The median age was 66.7 years
(range: 23–83.3 years).
A total of 113 patients (76.3%) underwent rad-
ical cystectomy alone. For concomitant upper tract
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urothelial carcinoma, 14 (9.5%) underwent si-
multaneous unilateral nephroureterectomy, and
21 (14.2%) underwent bilateral nephroureterec-
tomy. Urinary diversion was performed with ileal
conduit in 82 (55.4%), ileoneobladder in 15
(10.1%), Indiana pouch in seven (4.7%), and per-
cutaneous nephrostomy in seven (4.7%) patients.
Perioperative mortality occurred in four (2.7%)
patients.
Pathological staging showed that 122 (83.8%)
patients had no lymph node involvement, and
they comprised 23 (15.5%) patients with pT0,
three (2.0%) with pTis, eight (5.4%) with pTa, 
11 (7.4%) with pT1, 38 (25.7%) with pT2, 24
(16.2%) with pT3, and 16 (10.8%) with pT4 
tumors. Another 24 (16.2%) patients were staged
as having lymph node involvement (pN+). The
median number of pelvic lymph nodes retrieved
was 10 (range: 0–35). Concomitant prostate cancer
was found in 11 (11.2%) of the 98 male patients.
All were organ-confined (pT2). Seven (63.6%)
patients had a Gleason score of ≤ 6, and four
(36.4%) had a score of 7. During follow-up, none
of these patients had evidence of prostate cancer
recurrence.
The 5-year RFS and OS for all 148 patients
was 61% and 53%, respectively. Table 2 and
Figure 1 show the 5-year RFS and OS rates for
each pathological stage. The 5-year RFS and OS
for patients with only 1–3 positive lymph nodes
were 54% and 33%, respectively, whereas recur-
rence developed in all patients with ≥ 4 positive
lymph nodes (Table 2 and Figure 2).
A total of 44 patients (29.7%) developed can-
cer recurrence. Among those who experienced re-
currence, the median time to recurrence was 10.5
months. Of the 44 patients with recurrence, 16
(36.4%) had local recurrence, and 28 (63.6%)
had distant recurrence. Fourteen of the 16 local
recurrences developed within 2 years, with only
two late local recurrences at 45 and 46 months.
Twenty-two of the 28 distant recurrences devel-
oped within 2 years, with the latest recurrence at
65 months. Table 3 shows the median time to 
recurrence and recurrence patterns for each patho-
logical stage. Time to recurrence and the recurrence
patterns are shown in Table 3.
Table 4 shows the univariate and multivariate
analysis of the impact of clinical and patholog-
ical factors on survival. In univariate analysis, 
age > 60 years, pT4 tumors, nodal positive dis-
eases, and a lymph node density ≥ 0.2 were sig-
nificant. In multivariate analysis, only age > 60
years, pT4 tumors, and nodal positive diseases
were significant.
Table 1. Demographics of 148 bladder TCC
treated with radical cystectomy*
Median age (range) 66.7 (23.8–83.3)
Sex
Male 98 (66.2)
Female 50 (33.8)
Operation
RC 113 (76.3)
RC + unilateral NU 14 (9.5)
RC + bilateral NU 21 (14.2)
Diversion
Ileal conduit 82 (55.4)
Ileoneobladder 15 (10.1)
Indiana pouch 7 (4.7)
PCN 7 (4.7)
Perioperative mortality 4 (2.7)
Pathological stage
pT0 23 (15.5)
pTis 3 (2.0)
pTa 8 (5.4)
pT1 11 (7.4)
pT2 39 (26.4)
pT3 24 (16.2)
pT4 16 (10.8)
pN+ 24 (16.2)
Prostate cancer (n = 11)
Organ-confined 11
Gleason score = 7 4
Gleason score < 7 7
Nodes removed 10 (0–35)
Neoadjuvant C/T 8 (5.4)
Adjuvant C/T 1 (0.7)
Adjuvant R/T 3 (2.0)
*Data presented as n (%) or mean (range). RC = radical cystectomy;
NU = nephroureterectomy; PCN = percutaneous nephrostomy;
C/T = chemotherapy; R/T = radiotherapy.
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Figure 1. (A) The 5-year recurrence-free survival and (B) overall survival curves after radical cystectomy, grouped by
pathological stage.
Figure 2. (A) The 5-year recurrence-free survival and (B) overall survival curves after radical cystectomy, grouped by the
number of positive lymph nodes.
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Table 2. The 5-year recurrence-free survival (RFS) and overall survival (OS) of 148 patients with different
pathological stages after radical cystectomy*
n 5-year RFS 5-year OS
All 148 0.64 ± 0.05 0.53 ± 0.05
pT0 23 0.96 ± 0.04 0.80 ± 0.10
pTa, pT1, pTis 22 0.77 ± 0.10 0.66 ± 0.13
pT2 39 0.68 ± 0.09 0.62 ± 0.09
pT3 24 0.65 ± 0.11 0.59 ± 0.11
pT4 16 0.11 ± 0.11 0.09 ± 0.08
pN+ 24 0.37 ± 0.11 0.31 ± 0.12
LN(+) (1–3 nodes) 16 0.54 ± 0.14 0.33 ± 0.13
LN(+) (≥ 4 nodes) 8 0 N/A
*Data presented as n or estimated probability ± standard error. N/A = not available; LN = lymph nodes.
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Discussion
In the present study, we reported the oncological
outcomes of radical cystectomy for bladder can-
cer. The 5-year RFS and OS were 68% and 62%
for pT2, 65% and 59% for pT3, 11% and 9% for
pT4, and 37% and 31% for node-positive dis-
ease, respectively. Compared with the contempo-
rary series,3,4 we had a similar result for pT2, a
better result for pT3, and a slightly worse result
for pT4 disease. The improving survival in pT3
tumors could have been attributed to wider exci-
sion of the perivesical soft tissue. On the other
hand, the worse outcome in pT4 tumors might
have resulted from inadequate resection of the
surrounding involved organs. Meanwhile, a peri-
operative mortality rate of 2.7% is generally in
line with that of the contemporary series. These
results suggest that radical cystectomy with pelvic
lymph node dissection can be curative in a sig-
nificant number of patients with organ-confined
(pT0–pT2) and extravesical (pT3) bladder cancer,
with an acceptable mortality rate.
The majority (81.8%) of recurrences occurred
within 2 years after radical cystectomy, with the
latest recurrence developing at 65 months after
surgery. Therefore, the follow-up schedule should
be frequent in the first 2 years and extended to 
at least 5 years. We also analyzed the recurrence
patterns of each pathological stage: more than
half of the recurrence of pT3 and pT4 diseases
occurred in the pelvic cavity, compared with only
one quarter in organ-confined diseases (pT0–
pT2). The findings imply that more radical and
wider excision is required for local control of pT3
and pT4 tumors. Moreover, as advanced bladder
cancer (pT3, pT4 or pN+) recurs more rapidly, 
a more intensive follow-up schedule might be
warranted.
Neoadjuvant chemotherapy has been shown
to improve survival in invasive bladder cancer.5,6
A meta-analysis, including 11 trials and 3005 
patients, has shown a significant benefit associ-
ated with cisplatin-based chemotherapy, equiva-
lent to a 5% improvement in OS at 5 years; the
survival benefit of 5% exists regardless of tumor
Table 3. Time to recurrence and recurrence patterns after radical cystectomy
Recurrence patterns (%)
Stage Time to recurrence (mo)
Local Distant
pT0 14.0 0 100.0
pTa, pT1, pTis 24.5 25.0 75.0
pT2 19.0 27.3 72.7
pT3 8.0 57.1 42.9
pT4 5.0 55.6 44.4
pN+ 4.5 25.0 75.0
Table 4. Survival predictors of radical cystectomy for bladder cancer*
Univariate p Multivariate p
Age > 60 (yr) 2.03 (1.11–3.71) 0.02 1.04 (1.01–1.07) < 0.01
pT4 vs. pT0–3 5.39 (3.14–9.26) < 0.01 4.38 (2.09–9.19) < 0.01
LN(+) 2.63 (1.45–4.77) < 0.01 1.92 (1.25–2.98) 0.02
> 10 lymph nodes retrieved 1.03 (0.58–1.82) 0.92 1.24 (0.68–2.28) 0.48
LN density ≥ 0.2 3.16 (1.62–6.19) < 0.01 1.71 (0.52–5.68) 0.38
*Data presented as hazard ratio (95% confidence interval). LN = lymph nodes.
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stage (pT2, pT3, or pT4).6 In our series, only eight
(5.4%) patients received neoadjuvant chemother-
apy. Three of them achieved pT0 status in their
cystectomy specimen, and two were alive and re-
currence-free at 48 and 60 months. Although the
result seems to be promising, with the limited
case number and the nonrandomized basis, the
real effect of neoadjuvant chemotherapy could
not be analyzed in the present study.
Several factors have been shown to influence
survival after radical cystectomy, including age,
pathological T stage, nodal status, number of
lymph nodes retrieved, and lymph node density.7,8
These factors were analyzed in our series: age
> 60 years, pT4 tumors, and positive lymph nodes
were associated significantly with poor prognosis
in multivariate analysis. Herr et al have demon-
strated that a greater number of lymph nodes 
retrieved can improve survival regardless of the
nodal status.9 Similarly, it has been demonstrated
that extending the limits of pelvic lymph node
dissection can also improve survival.10,11 The effect
of lymph node removal could not be shown in
our analysis. This might be resulted from vari-
ability among the pathologists in terms of tech-
nique and diligence in examining the specimen
and searching for nodes.7 The number of lymph
nodes retrieved might have been underestimated
if the nodes were grossly normal. Therefore, the
number of lymph nodes retrieved was not precise.
As a consequence, the lymph node density could
not be calculated exactly.
Lymph node metastasis, even only one positive
node, is thought to represent systemic disease.12
Whether nodal-positive diseases can be cured with
surgery alone remains controversial. Several lines
of evidence have shown that radical cystectomy
along with pelvic lymph node dissection can
provide long-term survival, particularly for those
with localized primary tumors and minimal me-
tastatic nodal disease.13–15 In our series, we found
that 33% of the patients with only 1–3 positive
lymph nodes could be recurrence-free and have
long-term survival. On the contrary, all patients
with ≥ 4 positive lymph nodes eventually had 
recurrence. Our findings generally support the
concept that patients with only limited lymph
node involvement can be cured by surgery.
Concomitant prostate adenocarcinoma was
found in 11.2% of the cystectomy specimens in
the present study. Without a whole-mount prepa-
ration for pathological examination, it is unlikely
that the rate represented the real situation. Yang
et al have reported a 33% incidence of concomi-
tant prostate cancer in cystectomy specimens in
Taiwanese men;16 a rate that is similar to that 
in the United States. Although the rate reported
in our series was underestimated, our findings
showed that the majority of the concomitant pro-
state cancer was of low grade and early stage, and
was clinically insignificant, because no patients
had recurrence of prostate cancer.
In conclusion, radical cystectomy provides an
eradicative treatment for organ-confined (pT0–
pT2) and extravesical (pT3) bladder cancer. Age
>60 years, pT4 tumors, and nodal-positive diseases
are associated with poor prognosis. Patients with
limited (1–3) positive lymph nodes can be cured
by surgery, whereas those with ≥ 4 positive lymph
nodes eventually have recurrence. Concomitant
prostate adenocarcinoma is of low grade and early
stage, and is clinically insignificant.
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